Cardiovascular disease is becoming an increasingly serious challenge in aging societies. Yet treatment options for patients with severe cardiac disorders remain limited, and the development of new therapeutic strategies is an urgent priority. Our laboratory is committed to creating new treatments for heart disease through regenerative medicine, centered on the construction and functional maturation of cardiac organoids derived from iPS cells. Through this work, we hope to provide therapeutic options that are not dependent solely on transplantation, while also accelerating drug discovery through human cardiac disease modeling.

In this project, we place strong emphasis on bridging basic research and clinical application. By collaborating with specialists in medicine, engineering, pharmaceuticals, and biotechnology, we are working to establish the foundations of next-generation cardiovascular medicine. In particular, we promote the development of novel treatment strategies based on cell technologies and biomaterials, together with the systems needed to deliver these innovations to real clinical settings.

This challenge cannot be achieved without the collaboration of many researchers, clinicians, and industry partners. We believe that truly innovative therapies emerge when experts from different fields join forces and build on each other’s strengths. We hope to continue this challenge together with all who share the goal of creating next-generation cardiovascular medicine and delivering new hope to more patients.